Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > バイオシミラー

Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Vibecotamab, RUO) (HB714036)

Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Vibecotamab, RUO)
Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Vibecotamab, RUO)
Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Vibecotamab, RUO)
Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Vibecotamab, RUO)
価格(USD):
スペック:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

  • SDS

概要
カタログ番号HB714036
説明
Vibecotamab (HB714036) is a research-grade recombinant antibody targeting CD123. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性Human
アプリケーションELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種Chimeric
クローン性Monoclonal
アイソタイプIgG1-kappa/scFv-h-CH2-CH3
発現システム Mammalian cells
テスト済みアプリケーション WB
ターゲット IL-3R subunit alpha, IL-3 receptor subunit alpha, CD123, Interleukin-3 receptor subunit alpha, IL3R, IL-3R-alpha, IL3RA, IL-3RA, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
エンドトキシンレベル < 10 EU/mg
純度 >95% purity as determined by SDS-PAGE.
精製 Protein A/G purified from cell culture supernatant.
アクセッション番号 P26951 & P07766
形態 Liquid
保存バッファー 0.01M PBS pH 7.4

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

安定性と保存 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名Bispecific, XmAb14045, 2138442-13-2
背景Vibecotamab (XmAb®14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.
注意事項 For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
イメージ
  • Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Vibecotamab, RUO)

    Bioactivity

    Detects Human CD3E in indirect ELISAs.

  • Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Vibecotamab, RUO)

    Western blot

    Western blot analysis was performed using anti-CD3E monoclonal antibody at 1ug/mL on various samples.
    Lane 1: recombinant human CD3E (Catalog No: HY057011)
    Lane 2: negative control

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: [email protected]

ディストリビューターリスト